As the global pharmaceutical and nutraceutical industries demand higher stability and environmental standards, KORNNAC Pharma identifies a significant market shift from traditional softgels to Liquid-Filled Hard Capsules (LFHC). This transition represents more than a technical iteration; it is a strategic choice driven by bioavailability needs and supply chain flexibility.

Formulation Evolution: Why Global Pharma is Shifting to LFHC?

While softgels historically dominated the oily ingredient sector, they often face challenges with complex formulations. KORNNAC Pharma's technical research indicates that plasticizers in softgels (such as glycerin) can lead to moisture migration, causing ingredient degradation over time.

Addressing Cross-linking and Migration in Softgels

• Stability: Softgels are prone to cross-linking, which can prevent disintegration during shelf life. KORNNAC Pharma utilizes hard shells (Gelatin or HPMC) without plasticizers, physically eliminating these risks.

• Compatibility: LFHC technology supports oils, suspensions, pellets, and even "capsule-in-capsule" combinations, enabling synergistic multi-component delivery.

KORNNAC Pharma Technical Benchmarks: Evidence of Stability and Bioavailability

In B2B procurement, parametric evidence is the ultimate measure of a supplier's core competence. KORNNAC Pharma ensures technical reliability through automated precision filling lines.

Key Data: >99% Content Uniformity and 3-Fold Bioavailability Improvement

1. Dosing Precision: Powered by Canadian PTS fully automated production lines, KORNNAC Pharma maintains content uniformity above 99%, exceeding industry standards for potent API safety.

2. Absorption Performance: Comparative tests show that compared to solid dosages, KORNNAC Pharma's liquid-filling technology, utilizing self-emulsification and drug-loaded pellets, increases the bioavailability of poorly soluble ingredients from under 20% to 55%-70% (a 3-fold improvement).

3. Delivery Capacity: With a single-line capacity of 1.2 million capsules/day and a flexible MOQ of 200,000 capsules, we significantly reduce trial-and-error costs during the R&D phase.

Sustainability and Regulatory Compliance: TiO2-Free Clean Label Solutions

To meet market access regulations in North America and the EU, KORNNAC Pharma has pioneered clean-label technologies compliant with international standards.

• Titanium Dioxide-Free (TiO2-free): Responding to European bans, we offer patented opacifying formulas that ensure light protection without the use of TiO2.

• SLS-Free Options: Addressing specific market demands, we provide formulations without Sodium Lauryl Sulfate to meet stringent toxicological evaluations.

• Certifications: Our production facilities follow cGMP standards and are certified by HALAL, KOSHER, and ISO 9001/22000. EU registration is completed, and US DMF filing is in progress.

Conclusion: Driving the Future of Formulation with Technology

The transition from traditional softgels to liquid-filled hard capsules is more than a change in packaging; it is a breakthrough in pushing the limits of drug stability and bioavailability. With filling precision exceeding 99%, a 3-fold increase in bioavailability, and a daily production capacity of 1.2 million capsules, KORNNAC Pharma has become a strategic partner for pharmaceutical companies in North America and Europe looking to optimize complex formulations. In an increasingly regulated global market, partnering with a cGMP-compliant supplier that offers TiO2-free technology is essential for ensuring both regulatory compliance and the commercial success of a product throughout its lifecycle.